5/7/2012 9:55:54 AM
SAN FRANCISCO--(BUSINESS WIRE)--ActiveSite Pharmaceuticals, Inc., announced today the award of a competitively renewed Phase II SBIR grant from the National Eye Institute, at the National Institutes of Health (Bethesda, Maryland), in continuing support of ActiveSite’s R&D program on novel orally-active plasma kallikrein (PK) inhibitors for treatment of diabetic macular edema (DME), the primary vision-threatening complication of diabetes. This award adds to previous funding the company has received from the NIH and other sources for developing an oral small molecule to treat DME. The grant funds, which could total over $1.3 million, will be used to carry out preclinical safety and toxicology studies with ActiveSite’s lead drug candidate. These studies, once completed successfully, would allow for the compilation and filing of an IND application with the Food and Drug Administration (FDA), for initiating Phase I clinical trials.
comments powered by